FTH
Faeth Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 22 to Jul 1 ▲ 7 days of insider buys: $1.2M by 2 insiders, avg $24.02
- Jun 30 ▲ 3 funds open new positions (13F)
- Jul 15 Trading halt: Halt Resumed: FTH, trading resumed after LUDP (Volatility…
- Aug 21 Needham initiates
- Aug 31 ▼ Short interest jumps 32.8% to 1.10M
- Sep 9 TD Cowen initiates
- Sep 14 LUCID CAPITAL MARKETS initiates
- Sep 16 Guggenheim initiates
- Sep 30 ▼ Short interest jumps 56.8% to 2.07M
- Oct 16 William Blair initiates
- Nov 9 ▲ Faeth Therapeutics reported topline Phase 2 data for PIKTOR (serabel…
- Nov 9 ▲ Faeth Therapeutics announced positive preliminary Phase 2 topline re…
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $1.2M at an average $24.02. No open-market sales. Price is 61% below their cost.
- InstitutionsBULLISH
Q2 2026: 12 added (3 new), 1 trimmed or exited. Largest new: Avoro Capital Advisors $36.1M, Baker Bros. Advisors $32.2M.
- AnalystsBULLISH
18 of 19 rate it Buy or better. Every target is above the price.
- Short sellersBUILDING
Short interest +17.7% to 2.73M shares. 6.3 days to cover, ≈10.6% of shares.
- TrendDOWNTREND
62% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| Avoro Capital Advisors LLC | NEW | $36.1M |
| BAKER BROS. ADVISORS LP | NEW | $32.2M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | $26.1M |
| RA CAPITAL MANAGEMENT, L.P. | NEW | $18.1M |
| MARSHALL WACE, LLP | DOUBLED | $5.2M |
| UBS Group AG | DOUBLED | $538.5K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $510.4K |
| JANE STREET GROUP, LLC | DOUBLED | $502.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is below the lowest target. Median implies +503%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only REITERATE | |
| Nov 16, 2026 | 🔒 Fresh data, subscribers only REITERATE | |
| Nov 10, 2026 | Citigroup MAINTAIN | Buy |
| Nov 4, 2026 | Guggenheim MAINTAIN | Buy |
| Oct 27, 2026 | BTIG REITERATE | Buy |
| Oct 16, 2026 | William Blair INITIATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Parikh Anand Kiran President and CEO Oct 30, 2026 | GIFT | 100,000 sh |
Schayowitz Adam Director Oct 23, 2026 | AWARD | 25,000 sh |
Vousden Karen H Director Sep 11, 2026 | AWARD | 25,000 sh |
Parikh Anand Kiran President and CEO Jul 21, 2026 | AWARD | 398,018 sh |
Craver Josiah PAO Jul 21, 2026 | AWARD | 30,824 sh |
STEPHENSON BRIAN C Chief Financial Officer Jul 1, 2026 | BUY | $103.0K |
STEPHENSON BRIAN C Chief Financial Officer Jul 1, 2026 | BUY | $14.5K |
STEPHENSON BRIAN C Chief Financial Officer Jun 30, 2026 | BUY | $43.8K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.88 | -$0.88–-$0.88 | -12.1% | $0.00 |
| Next Q | -$0.89 | -$0.89–-$0.89 | +0.0% | $0.00 |
| Current FY | -$15.60 | -$15.60–-$15.60 | -13.2% | $0.00 |
| Next FY | -$3.67 | -$4.96–-$2.03 | +18.3% | $0.00 |
Short side
FINRA· Oct 30, 2026| Jul 15, 2026 | Volatility Pause | Resumed |
SecBot reports
12 filings · 2 bullish · 1 bearish · 9 neutral- NEUTRAL SC 13GNov 16, 2026
Avoro Capital Advisors LLC filed a Schedule 13G disclosing a 5.46% passive stake in Faeth Therapeutics as of September 30, 2026. Avoro holds 1,410,000 shares on behalf of Avoro Life Sciences Fund LLC. The filing certifies passive intent and is an initial 13G from this filer.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 13, 2026
Montanova Capital, LLC filed an amended Schedule 13G disclosing a 8.9% passive stake in Faeth…
Monitor for any future conversion to a 13D filing, which would signal activist intent. The passive nature of this stake suggests no near-term governance changes.
- BULLISH 8-KNov 9, 2026
Faeth Therapeutics reported topline Phase 2 data for PIKTOR (serabelisib + sapanisertib) plus…
The Phase 2 data provide a foundation for registrational trial design. Key catalysts to watch: disclosure of pivotal trial design by 1H 2027, data update at a medical meeting in mid-2027, and Phase…
- BULLISH 8-KNov 9, 2026
Faeth Therapeutics announced positive preliminary Phase 2 topline results for PIKTOR (serabelisib…
The 33% ORR and 7.4-month mPFS compare favorably to the 3-4 months typical for salvage chemotherapy alone, per management. Watch for regulatory alignment discussions and Phase 3 trial design…
All FTH filing & press-release reports (12)
- SC 13G reportNov 16, 2026
- SC 13G/A reportNov 13, 2026
- 8-K reportNov 9, 2026
- 8-K reportNov 9, 2026
- 8-K reportNov 3, 2026
- 3 reportOct 27, 2026
- 8-K reportOct 27, 2026
- 3 reportSep 15, 2026
- 144 reportAug 11, 2026
- 8-K reportAug 4, 2026
- 3 reportJul 28, 2026
- CLUSTER reportJul 1, 2026